SOFTWARE TOOL ARTICLE

VIRdb 2.0: Interactive analysis of comorbidity conditions associated with vitiligo pathogenesis using co-expression network-based approach [version 1; peer review: 3 approved with reservations]

Priyansh Srivastava , Mehak Talwar, Aishwarya Yadav, Alakto Choudhary, Sabyasachi Mohanty , Samuel Bharti , Priyanka Narad , Abhishek Sengupta

Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, 201301, India

V1 First published: 27 Aug 2020, 9:1055
<https://doi.org/10.12688/f1000research.25713.1>
 Latest published: 01 Feb 2021, 9:1055
<https://doi.org/10.12688/f1000research.25713.2>

Abstract

Vitiligo is a disease of mysterious origins in the context of its occurrence and pathogenesis. The autoinflammatory theory is perhaps the most widely accepted theory that discusses the occurrence of Vitiligo. The theory elaborates the clinical association of vitiligo with autoimmune disorders such as Psoriasis, Multiple Sclerosis and Rheumatoid Arthritis and Diabetes. In the present work, we discuss the comprehensive set of differentially co-expressed genes involved in the crosstalk events between Vitiligo and associated autoimmune disorders (Psoriasis, Multiple Sclerosis and Rheumatoid Arthritis). We progress our previous tool, Vitiligo Information Resource (VIRdb), and incorporate into it a compendium of Vitiligo-related multi-omics datasets and present it as VIRdb 2.0. It is available as a web-resource consisting of statistically sound and manually curated information. VIRdb 2.0 is an integrative database as its datasets are connected to KEGG, STRING, GeneCards, SwissProt, NPASS. Through the present study, we communicate the major updates and expansions in the VIRdb and deliver the new version as VIRdb 2.0. VIRdb 2.0 offers the maximum user interactivity along with ease of navigation. We envision that VIRdb 2.0 will be pertinent for the researchers and clinicians engaged in drug development for vitiligo.

Keywords

Vitiligo, Database, Comorbidity Network, Differential Genes, co-expressed Genes

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 01 Feb 2021	 view		
version 1 27 Aug 2020	 view	 view	 view

1. **Dinesh Gupta** , International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India
2. **Mitesh Dwivedi** , Uka Tarsadia University, Surat, India
Rasheedunnisa Begum , Maharaja Sayajirao University of Baroda, Vadodara, India
3. **Animesh A Sinha**, University at Buffalo, The State University of New York, Buffalo, USA

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Bioinformatics** gateway.

Corresponding authors: Priyanka Narad (pnarad@amity.edu), Abhishek Sengupta (asengupta@amity.edu)

Author roles: **Srivastava P:** Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Talwar M:** Data Curation, Visualization, Writing – Original Draft Preparation; **Yadav A:** Methodology, Visualization, Writing – Original Draft Preparation; **Choudhary A:** Data Curation; **Mohanty S:** Data Curation; **Bharti S:** Data Curation, Formal Analysis, Methodology, Software, Validation, Visualization; **Narad P:** Project Administration, Supervision, Validation, Writing – Review & Editing; **Sengupta A:** Conceptualization, Project Administration, Supervision, Validation

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Srivastava P *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Srivastava P, Talwar M, Yadav A *et al.* **VIRdb 2.0: Interactive analysis of comorbidity conditions associated with vitiligo pathogenesis using co-expression network-based approach [version 1; peer review: 3 approved with reservations]** F1000Research 2020, 9:1055 <https://doi.org/10.12688/f1000research.25713.1>

First published: 27 Aug 2020, 9:1055 <https://doi.org/10.12688/f1000research.25713.1>

Introduction

Vitiligo is a long-term pigmentary disorder of ambiguous origins. It is a multifactorial disease described by a plethora of theories¹. As stated in neural theory, the dysfunction of the sympathetic nervous system affects melatonin production which leads to depigmentation². The oxidative stress hypothesis states that vitiliginous skin is the result of the overproduction of reactive oxygen species such as H_2O_2 leading to the demolition of melanocytes that results in depigmentation³. The zinc- α 2-glycoprotein (ZAG) deficiency hypothesis exploits the integral role of ZAG, which acts as a keratinocyte derived factor responsible for rapid melanocyte production⁴. Absence of ZAG results in the detachment of melanocytes from epidermis which leads to vitiligo⁴. Chronic hepatitis C virus and autoimmune hepatitis have strong union with vitiligo and account for viral origins⁵. According to Intrinsic theory, melanocytes may have natural defects such as abnormal rough endoplasmic reticulum or deficiency of growth factors which could lead to melanocyte apoptosis⁶. The Autoinflammatory theory is the most widely accepted causation supported by strong evidence⁷. The hypothesis is mainly based on the clinical association of vitiligo with several other autoimmune disorders like psoriasis (PS), multiple sclerosis (MS) or rheumatoid arthritis (RA)^{8–11}.

Vitiligo Information Resource (VIRdb) is home to statistically significant and manually curated information about vitiligo¹². In our previous work, we integrated drug-target and systems-based approaches to generate a comprehensive resource for vitiligo-omics. Data stored in VIRdb is linked with major public databases making it a cross-functional database^{12–17}. It is an encyclopedic resource consisting of 129 differentially expressed genes (DEGs) in different phenotypes of vitiligo¹². It also holds 40 curated protein targets along with their natural ligands that are derived through virtual screening¹². In the present work, we aim to provide a comprehensive set of DEGs involved in the crosstalk events of vitiligo and associated autoimmune disorders (PS, MS, RA). We further investigated the interactions of the gene through comorbidity gene-gene interaction network (GGI). All data have been synthesized using standardized differential-expression pipelines. The data presented in the present study have been integrated on the VIRdb along with the previously published datasets. The paper also discusses the major updates and expansions in the VIRdb and delivers the new version as VIRdb 2.0¹⁸.

Results

Differentially expressed genes

The expression set for each disease (vitiligo, MA, RA and PS) constituted expression values of 27,338 probe IDs that belong to the Affymetrix GPL570 platform. After differential expression analysis, 834 differential genes were expressed in vitiligo (Lesional, Peri-lesional and Non-lesional together) out of which 639 genes were over-expressed and 195 genes were under-expressed (*Extended data*, Appendix-I). In RA samples a total of 938 genes were expressed, out of which 422 genes were over-expressed and 516 genes were under-expressed in the diseased condition (*Extended data*, Appendix-I). For MS 1783 differentially expressed genes were filtered in which 710 genes were

over-expressed and 1073 genes were under-expressed (*Extended data*, Appendix-I). In PS, 4016 differentially expressed genes were filtered out in which 2088 were over-expressed and 1928 were under-expressed (*Extended data*, Appendix-I).

Correlated Expressions

Pearson's correlation analysis on DEGs (vitiligo) produced 397 pairs that were positively correlated with each other (*Extended data*, Appendix-II¹⁹). Interestingly, we found none of the gene-pairs to be under-expressed in vitiligo except the *FKBP5-CUL7*. In PS there were a total of 1089 positively correlated pairs out of which the 45 pairs were showing under-expression and 1044 pairs were showing over-expression (*Extended data*, Appendix-II¹⁹). A skewness towards over-expressed pairs can be seen in the pairs positively correlated with PS. Pearson's correlation testing of MS-DEGs generated 767 positively correlated pairs, with 623 under-expressed pairs and 144 over-expressed pairs (*Extended data*, Appendix-II¹⁹). Testing of RA-DEGs produced the least number of positively correlated pairs, i.e. 411, in which 301 pairs were under-expressed and 110 pairs were over-expressed (*Extended data*, Appendix-II¹⁹). It showed skewness towards the under-expressed pairs.

Intersecting genes

PS shared 26 differentially expressed (positive co-expressed) genes with vitiligo. In total, 23 differentially expressed genes showed similar expression (Over-expression) both in the vitiligo and PS (*Figure 1a*). However, *ZNF395*, *INTS6* and *BBX* showed an opposite expression in PS (*Figure 1a*). MS and vitiligo shared 37 differentially expressed (positive co-expressed) genes, all of which showed contradictory expressions except *SPEN*, *NEAT1*, *MIR612*, *MALT1* and *KMT2A* (similar expression) (*Figure 1b*). RA shared 24 differentially expressed (positive co-expressed) genes with the vitiligo and showed randomness in the expression (*Figure 1c*).

Network Attributes

The GGI network of the intersecting positively correlated DEGs of vitiligo and PS holds 38 nodes with 93 edges denoting the co-expression, physical interactions and pathway relationships mined from literature (*Extended data*, Appendix-IV¹⁹) (*Figure 2a*). GeneMania's algorithm also fetched 12 intermediary genes to connect the shared 26 differentially expressed (positive co-expressed) genes (*Extended data*, Appendix-IV¹⁹). the network for vitiligo and MS holds 51 nodes and 219 edges mined from literature, having 14 intermediary genes (*Extended data*, Appendix-IV¹⁹) (*Figure 2b*). The GGI network of RA and vitiligo constituted 33 nodes and 470 edges, out of which 9 nodes (genes) were intermediary genes that were fetched by GeneMania's algorithm (*Extended data*, Appendix-IV¹⁹) (*Figure 2c*).

Enrichments and annotations

Mechanical annotation of the genes from the GGI network of vitiligo and PS shows the highest expressivity in chromosome 14. Chromosome 18-21 doesn't express at all (*Extended data*, Appendix-V¹⁹) (*Figure 3*). Genes of the GGI network

Figure 1. Intersecting genes with relative LogFC. (a) Positively correlated DEGs common between vitiligo and PS; (b) Positively correlated DEGs common between vitiligo and MS; (c) Positively correlated DEGs common between vitiligo and RA.

Figure 2. Gene-gene interaction networks designed using GeneMania. (a) GGI Network for common positively correlated DEGs between vitiligo and PS. (b) GGI Network for common positively correlated DEGs between vitiligo and MS. (c) GGI Network for common positively correlated DEGs between vitiligo and RA.

of vitiligo and MS were expressed mainly on chromosomes 1, 7 and 12 (*Extended data, Appendix-V¹⁹*) (*Figure 3*). Nodes from the GGI network of vitiligo and RA showed no expression through chromosomes 2, 8-10, 15, 16, 18, 21 and 22 (*Extended data, Appendix-V¹⁹*) (*Figure 3*). Expression was not seen through chromosome Y in any case (*Extended data, Appendix-V¹⁹*) (*Figure 3*). Intersecting genes of the GGI network of vitiligo and PS were mostly (23/36) enrichment with “Cellular protein metabolic process” as a biological process (*Extended data, Appendix-VI¹⁹*). MS and vitiligo network was enriched in “Regulation of innate immune response” (8/50) as a biological process (*Extended data, Appendix-VI¹⁹*). “RNA binding” (24/32) was enriched as the biological process for the nodes of the RA and vitiligo network (*Extended data, Appendix-VI¹⁹*).

Updates and expansions

VIRdb 2.0¹⁸ offers an engaging user-interface along with interactive visualizations. Data descriptors have been added to the

browsing interface for effortless navigation through the data (*Figure 4a*)¹². The JSmol visualizer of the protein profiles has been optimised for quick visualizations (*Figure 4b*)¹². The profiles have cross-connectivity to other databases through their respective Accession IDs. The user can now visualize the protein structure in various styles (i.e. cartoon, ribbons, etc.) using JSmol options. The downloadable structure has been already prepared for molecular docking procedures (i.e. removed the water, ions, chargers, ligands and minimized with OPLS 2005) (*Figure 4b*)¹². The natural leads section has been reduced to the top 50 computational hits against the protein targets (*Figure 4c*)¹². The user can browse through fewer compounds before setting up wet lab experimentations (*Figure 4c*)¹². Intersecting positively co-expressed DEGs between vitiligo and other conditions (PS, RA and MS) is the new addition to the database (*Figure 5b*). The section consists of four columns which are connected to GeneCards via gene symbols. The section holds expression status (Overexpression/Underexpression) of the positively co-expressed

Figure 3. Chromosomal distribution of the intersecting DEGs. Red bars show the distribution of the intersecting DEGs between vitiligo and MS. Green bars show the distribution of the intersecting DEGs between vitiligo and PS. Blue bars show the distribution of the intersecting DEGs between vitiligo and RA.

DEGs between vitiligo and associated conditions (Figure 5b). The GGI networks which are made using the shared positively co-expressed DEGs between vitiligo and other conditions can be viewed in the network gallery section (Figure 5c). The networks are highly interactive and can be simulated with mouse clicks.

Methods

Data Curation

Raw datasets from the microarray studies for RA (GSE56649), PS (GSE14905), MS (GSE21942), and vitiligo (GSE65127) were downloaded from the Gene Expression Omnibus (GEO)²⁰. To maintain the uniformity of the downstream analysis, experiments with Affymetrix GPL570 platform were taken into consideration. Expression values were extracted from the raw CEL files using the *affy* (version 1.66.0) library in R version 3.6²¹. Expression datasets were normalized using the robust multichip averaging method for background corrections²². After the normalization, the IQR method was used with a standard cut-off of 0.5 to remove the low expression values from the datasets using *genefilter* (version 1.70.0) library²³. Each dataset was divided into two groups based on the phenotype of the samples, i.e. “Experiment” (disease phenotypes) and “Control” (healthy phenotypes). Specifically, for vitiligo expression set, “Experiment” groups constituted of lesional, peri-lesional and non-lesional vitiligo samples together. Scripts used for computational analysis of data generated through microarray experiments are available on Github: <https://github.com/pnrad/Micro-Array-Data-Analysis>²⁴.

Differential Expression Analysis

Standard linear models’ library *limma* (version 3.44.3) was used to perform the differential expression analysis²⁵. The t-test was performed with each gene expression value to examine variations across groups (“Experiment” vs “Control”). Benjamini Hochberg’s false discovery rate was computed to filter the significant multiple testings²⁶. P-value cut-off of 0.05 and adjusted-P-value (FDR) cut-off of 0.03 was used to filter the significant test results. Log of fold change (LogFC) across groups was calculated alongside with standard “limma” functions to explore the expression status of the differentially expressed probes ids. Probe Ids with LogFC < -0.5 were annotated as underexpressed and those with LogFC > 0.5 were annotated as overexpressed in “Experiment” samples and the remaining probe ids were dropped (i.e. -0.5 < LogFC < 0.5).

Probe mappings

The respective feature dataset that contains the gene symbol mapping for the probe id fetched from the GEO using “GEOquery”²⁷. The differentially expressed probe ids were mapped to their respective gene symbols programmatically²⁸. The gene symbols that were mapped to multiple probe ids with different expression status (i.e. ambiguity in over/under-expression) were removed using *dplyr* (version 1.0.1) methods²⁹. The gene symbols which were mapped on multiple probe ids with uniform expression (i.e. uniformity in over/under-expression) were averaged over the calculated parameters (i.e. P-value, adjusted P-value, average expression etc.). The final datasets constituted

Figure 4. Improvisations on the User-interface of the VIRdb. (a) The browsing section has been redesigned with descriptors for easy navigation through the database. (b) JSmol has been optimized for various visualization styles which can be enabled using right-click. (c) The Natural lead section has been reduced to the top entries based on the significant Glide-Scores.

Figure 5. (a) Revamped home page of the VIRdb 2.0 with all the section tabs for easier navigation; **(b)** Intersection section displays the positively co-expressed DEGs across PS, vitiligo, MS and RA. Gene symbols are cross-connected with GeneCards db. **(c)** Network gallery section with D3-force layout. It offers a highly interactive network visualization of the comorbidity networks.

Figure 6. Updated Database Schema for Vitiligo Information Resource 2.0. Network Gallery and Intersecting Gene sections have been added with cross-connectivity and D3 force-directed graph visuals.

unique differentially expressed genes in “Experimental” samples of all the four diseases.

Correlations and intersections

The correlated pairs (similar expressions across the samples) were formed within the disease groups (i.e. MS, RA, PS and vitiligo) individually. Initially, the differentially expressed gene symbols were reverse mapped to their respective probe ids for extraction of expression values. Pearson’s correlation test was performed to compute the correlation coefficient. The correlation matrix was filtered for correlations having a correlation coefficient $> \pm 0.9$. The probe IDs were re-mapped to the gene symbols along with LogFC. The negatively correlated pairs were removed using the LogFC (i.e. different expression status of gene in a pair), and only positive correlated differential pairs were taken for further analysis³⁰. Cytoscape (version 3.8) was used to create four individual co-expression networks using the differentially expressed and positively correlated gene pairs³¹. The co-expression networks for MS, RA and PS were individually intersected with the co-expression network of vitiligo for evaluation of commonly expressed genes across diseases.

Gene-gene interaction network reconstruction

The intersecting genes were fed to **GeneMania** for edge-reconstruction of the comorbidity gene interaction networks (i.e. vitiligo with RA, vitiligo with MS and vitiligo with PS)³². The intersecting gene symbols were joined using annotated edges of GeneMania algorithm. We dropped “predicted” edges and selected the rest of the edges which were sourced from the literature. The networks were examined using Cytoscape and the largest connected subnetworks were isolated.

Annotations and ontologies

The gene symbols from each dataset were fed to the **g:Profiler** server for gene ontologies³³. The Benjamini–Hochberg false discovery rate of 0.03 was chosen with an annotated domain scope for enrichment analysis. Finally, network nodes were annotated using the **biomaRt** (version 2.44.1) data mining tool for chromosome number, start base-pair and stop base-pairs³⁴. The three comorbidity network datasets were mapped with their respective LogFC for meaningful insights

Updated architecture and design

The previous schema of the database was updated with the new addition of Network Gallery and Intersecting Gene’s sections (Figure 3). Bootstrap objects were added for styling along with HTML 5 and CSS in the front-end stack. JavaScript was added for dynamic visualizations of JSmol viewer and D3 force-directed networks based on Verlet integration^{35–37}.

Operation

The VIRdb 2.0¹⁸ is available online as an open-source database. The user can access the database through any platform (Linux, Mac OS, or Windows). There are no specific system requirements to browse the database. The user can browse through different sections using the easy to use interface.

Implementation

The database is implemented in various sections. Intersection section displays the positively co-expressed DEGs across PS, vitiligo, MS, and RA. Gene symbols are cross connected with GeneCards db. Network gallery section of the database offers a highly interactive network visualization of the comorbidity

networks. The JSmol viewer has been optimized for various visualization styles which can be enabled using right-click. The user can visualize the structure in various styles such as cartoons, ribbons etc. The Natural lead section has been reduced to the top entries based on the significant Glide-Scores.

Discussion

The present study discusses the comorbidities of the vitiligo with known associative disorders based on auto-inflammatory theory^{8–11}. With the aid of statistical procedures, we found significant DEGs that show correlated expressions in vitiligo, PS, MS and RA. *ZNF395* which activates a subset of ISGs including the chemokines *CXCL10* and *CXCL11* in keratinocytes was co-expressed between the PS and vitiligo³⁸. *CXCL10* and *CXCL11*, are expressed in skin keratinocytes and are involved in the development of proinflammatory skin diseases such as vitiligo³⁸. *ZNF395* was over-expressed in our dataset of positively co-expressed DEGs from vitiligo samples and was under-expressed in samples of PS (*Extended data*, Appendix-III¹⁹). *ZNF395* has direct associations with Huntington's disease and might be a crucial biomarker in vitiligo-PS auto-immune progression as well³⁹. *CSNK1A1*, which was expressed in all the conditions showed under-expression in MS and therefore could be used as a biomarker for MS (*Extended data*, Appendix-III¹⁹). It is also interesting to see that most of the shared DEGs in PS and RA show uniform expression like vitiligo. However, the expressions of DEGs shared with MS show contradictory expressions, which points towards a weaker association between vitiligo and MS. The presented comorbidity networks hold many new DEGs which are shared among the auto-immune diseases. These DEGs can be explored for their cross-talks events as supported by auto-inflammatory theory⁷.

VIRdb 2.0¹⁸ integrates statistically significant DEGs that could be responsible for crosstalk events between vitiligo, PS, MS and RA. VIRdb 2.0 incorporates all the attributes of the previous version and projects them in a more user-friendly database. The intersecting DEGs with other diseases (PS, MS and RA) are projected with their expression status in diseases. VIRdb 2.0 also utilizes a network approach to project positively co-expressed genetic interaction networks of the intersecting differentially expressed genes. VIRdb 2.0 also offers the maximum user interactivity with the D3 layouts. The users can now visualize the GGI networks and minimized protein structures directly on the database. The visualization tools (JSmol and D3-simulator) allow switching between various poses. The datasets can be downloaded in a zipped archive with few clicks from the download section. Thus, VIRdb 2.0 will be pertinent for the researchers and clinicians engaged in drug development and genomics of vitiligo.

Conclusion

We present VIRdb 2.0, intersecting differential networks that could be responsible for cross-talks events between vitiligo,

PS, MS and RA. The presented networks are designed using the common positively co-expressed DEGs in the disease. The VIRdb 2.0 inherits all the previous datasets of VIRdb and incorporates new datasets that are discussed in the present study. Future versions will include data submission capabilities and functional-omics perspectives.

Data availability

Underlying data

Extended data

Figshare: VIRdb 2.0: Interactive analysis of comorbidity conditions associated with vitiligo pathogenesis using co-expression network-based approach. <https://doi.org/10.6084/m9.figshare.12776468.v1>¹⁹.

This project contains the following extended data:

- Appendix-I (Differential Genes).xlsx. (Results of the differential expression analysis.)
- Appendix-II (Positive Correlations).xlsx. (Results of the Pearson's correlation testing.)
- Appendix-III: (Intersection results of the differential genes.)
- Appendix-IV (Networks).xlsx. (Network files of the GGI networks constructed through GeneMania.)
- Appendix-V (Annotations).xlsx. (Results of the gene annotation using the BioMart Data Mining tool.)
- Appendix-VI (Ontologies).xlsx. (Results of Gene Ontology enrichment analysis.)

Scripts used for data analysis are available from: <https://github.com/pnarad/Micro-Array-Data-Analysis>.

Archived scripts at time of publication: <https://doi.org/10.5281/zenodo.3975638>²⁴.

License: MIT License.

Software availability

VIRdb 2.0 is available at: <https://vitiligoinfores.com/>.

Source code available from: <https://github.com/pnarad/VIRdb>.

Archived source code at the time of publication: <https://doi.org/10.5281/zenodo.3975634>¹⁸.

VIRdb license: Creative Commons Attribution 4.0 International.

Source code license: Creative Commons Zero "No rights reserved" data waiver.

References

- Malhotra N, Dytoc M: **The Pathogenesis of Vitiligo.** *J Cutan Med Surg.* 2013; **17**(3): 153–172.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kotb El-Sayed M, Abd El-Ghany A, Mohamed R: **Neural and Endocrine Pathobiochemistry of Vitiligo: Comparative Study for a Hypothesized Mechanism.** *Front Endocrinol (Lausanne).* 2018; **9**: 197.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- He Y, Li S, Zhang W, *et al.*: **Dysregulated autophagy increased melanocyte sensitivity to H2O2-induced oxidative stress in vitiligo.** *Sci Rep.* 2017; **7**: 42394.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bagherani N: **The Newest Hypothesis about Vitiligo: Most of the Suggested Pathogenesis of Vitiligo Can Be Attributed to Lack of One Factor, Zinc- α 2-Glycoprotein.** *ISRN Dermatol.* 2012; **2012**: 405268.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rahman R, Hasija Y: **Exploring vitiligo susceptibility and management: a brief review.** *Biomedical Dermatology.* 2018; **2**: 20.
[Publisher Full Text](#)
- Taieb A: **Intrinsic and Extrinsic Pathomechanisms in Vitiligo.** *Pigment Cell Res.* 2000; **13**(Suppl 8): 41–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ezzedine K, Eleftheriadou V, Whittom M, *et al.*: **Vitiligo.** *Lancet.* 2015; **386**(9988): 74–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schallreuter KU, Lemke R, Brandt O, *et al.*: **Vitiligo and Other Diseases: Coexistence or True Association? Hamburg study on 321 patients.** *Dermatology.* 1994; **188**(4): 269–275.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Birlea S, Fain P, Spritz R: **A Romanian Population Isolate With High Frequency of Vitiligo and Associated Autoimmune Diseases.** *Arch Dermatol.* 2008; **144**(3): 310–316.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Diallo A: **Halo Nevi Association in Nonsegmental Vitiligo Affects Age at Onset and Depigmentation Pattern.** *Arch Dermatol.* 2012; **148**(4): 497–502.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ramagopalan S, Dymment D, Valdar W, *et al.*: **Autoimmune disease in families with multiple sclerosis: a population-based study.** *Lancet Neurol.* 2007; **6**(7): 604–610.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Srivastava P, Choudhury A, Talwar M, *et al.*: **VIRdb: a comprehensive database for interactive analysis of genes/proteins involved in the pathogenesis of vitiligo.** *PeerJ.* 2020; **8**: e9119.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kanehisa M: **KEGG: Kyoto Encyclopedia of Genes and Genomes.** *Nucleic Acids Res.* 2000; **28**(1): 27–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mering C: **STRING: a database of predicted functional associations between proteins.** *Nucleic Acids Res.* 2003; **31**(1): 258–261.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Safran M, Dalah I, Alexander J, *et al.*: **GeneCards Version 3: the human gene integrator.** *Database (Oxford).* 2010; **2010**: baq020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bairoch A: **The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000.** *Nucleic Acids Res.* 2000; **28**(1): 45–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zeng X, Zhang P, He W, *et al.*: **NPASS: natural product activity and species source database for natural product research, discovery and tool development.** *Nucleic Acids Res.* 2017; **46**(D1): D1217–D1222.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Srivastava P: **pnnad/Micro-Array-Data-Analysis: VIRdb: Micro-Array-Data-Analysis (Version v.2.0).** *Zenodo.* 2020.
<http://www.doi.org/10.5281/zenodo.3975634>
- Sengupta A, Narad P: **VIRdb 2.0: Interactive analysis of comorbidity conditions associated with vitiligo pathogenesis using co-expression network-based approach.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.12776468.v1>
- Barrett T, Edgar R: **Gene Expression Omnibus: Microarray Data Storage, Submission, Retrieval, and Analysis.** *Methods Enzymol.* 2006; **411**: 52–369.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gautier L, Cope L, Bolstad B, *et al.*: **affy--analysis of Affymetrix GeneChip data at the probe level.** *Bioinformatics.* 2004; **20**(3): 307–315.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Irizarry R: **Exploration, normalization, and summaries of high-density oligonucleotide array probe level data.** *Biostatistics.* 2003; **4**(2): 249–264.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gentleman R, Carey V, Huber W, *et al.*: **Genefilter: methods for filtering genes from high-throughput experiments.** 2015; **1**(1).
- Bharti S: **pnnad/VIRdb: Source code of the database:VIRdb (Version v.2.0).** *Zenodo.* 2020.
<http://www.doi.org/10.5281/zenodo.3975638>
- Ritchie M, Phipson B, Wu D, *et al.*: **limma powers differential expression analyses for RNA-sequencing and microarray studies.** *Nucleic Acids Res.* 2015; **43**(7): e47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chen S, Feng Z, Yi X: **A general introduction to adjustment for multiple comparisons.** *J Thorac Dis.* 2017; **9**(6): 1725–1729.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Davis S, Meltzer PS: **GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor.** *Bioinformatics.* 2007; **23**(14): 1846–1847.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Introduction to data.table.** Cran.r-project.org. Published in 2020. Accessed July 10, 2020.
[Reference Source](#)
- Introduction to dplyr.** Cran.r-project.org. Accessed July 10, 2020.
[Reference Source](#)
- van Dam S, Vösa U, van der Graaf A, *et al.*: **Gene co-expression analysis for functional classification and gene-disease predictions.** *Brief Bioinform.* 2018; **19**(4): 575–592.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Shannon P, Markiel A, Ozier O, *et al.*: **Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks.** *Genome Res.* 2003; **13**(11): 2498–2504.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mostafavi S, Ray D, Warde-Farley D, *et al.*: **GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function.** *Genome Biol.* 2008; **9** Suppl 1(Suppl 1): S4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Raudvere U, Kolberg L, Kuzmin I, *et al.*: **g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update).** *Nucleic Acids Res.* 2019; **47**(W1): W191–W198.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Smedley D, Haider S, Durinck S, *et al.*: **The BioMart community portal: an innovative alternative to large, centralized data repositories.** *Nucleic Acids Res.* 2015; **43**(W1): W589–W598.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Herráez A: **Biomolecules in the computer: Jmol to the rescue.** *Biochem Mol Biol Educ.* 2006; **34**(4): 255–261.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bostock M: **Force-Directed Graph.** Observablehq.com. Accessed July 18, 2020.
[Reference Source](#)
- Rozmanov D, Kuslik PG: **Robust rotational-velocity-Verlet integration methods.** *Phys Rev E Stat Nonlin Soft Matter Phys.* 2010; **81**(5 Pt 2): 056706.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schroeder L, Herwartz C, Jordanovski D, *et al.*: **ZN395 Is an Activator of a Subset of IFN- γ -Stimulated Genes.** *Mediators Inflamm.* 2017; **2017**: 1248201.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nopoulos PC: **Huntington disease: a single-gene degenerative disorder of the striatum.** *Dialogues Clin Neurosci.* 2016; **18**(1): 91–98.
[PubMed Abstract](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ? ? ?

Version 1

Reviewer Report 11 January 2021

<https://doi.org/10.5256/f1000research.28377.r75274>

© 2021 Sinha A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Animesh A Sinha

Department of Dermatology, University at Buffalo, The State University of New York, Buffalo, NY, USA

This is an overall well written paper comparing transcriptional datasets in vitiligo to other autoimmune disease datasets.

Building on previous work, the authors further develop their software for integrative analysis.

Comments:

1. Intro: the Specific goals of the study and the previous work by the authors relevant to this study should be further explained.
2. It is not clear that all published and available datasets for VL and the other autoimmune diseases have been incorporated into the program. A Table of all relevant studies should be provided in the manuscript or supplemental data.
3. The site itself would benefit from tutorials and a better search function.
4. Some more extensive data on disease intersecting genes and functional pathways should be included.

Is the rationale for developing the new software tool clearly explained?

Yes

Is the description of the software tool technically sound?

Yes

Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?

Partly

Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?

Partly

Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunogenetics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 27 Jan 2021

Abhishek Sengupta

Dear Sir,

We thank you for the generous and concise comments on our manuscript. We have incorporated the suggestions and changes have been added to the manuscript text also.

Q.1 Intro: the Specific goals of the study and the previous work by the authors relevant to this study should be further explained.

As per the suggestion, we have incorporated a few lines about the specific goals of the study as well as the explained our previous work briefly. We have given the reference to our previously published paper to be explored in more detail.

Q.2 It is not clear that all published and available datasets for VL and the other autoimmune diseases have been incorporated into the program. A Table of all relevant studies should be provided in the manuscript or supplemental data.

We have mentioned in our previous paper the dataset that was used for Vitiligo and the inclusion and exclusion criterion for all the available datasets. To briefly answer your question, Gene Expression Omnibus was manually queried using "(“vitiligo” (MeSH Terms) OR vitiligo (All Fields)) AND (“humans” (MeSH Terms) OR “Homo sapiens” (Organism) OR homo sapiens (All Fields))”. The returned results were manually curated for microarray experiments having healthy controls against affected individuals only for both the VL and other autoimmune diseases that we have considered in our work. As no plausible Our primary focus was on microarray data and no plausible data was available having an adequate amount of data for analysis so other autoimmune diseases were excluded. We aim to work on more data and include more information in the further prospects of this project.

Q.3 The site itself would benefit from tutorials and a better search function.

A short tutorial has been incorporated at the Home page highlighting the sections and the process of retrieval from the sections. Complete code for accessing the

database is already available at GitHub. A new page has been created to highlight "what's new in this release".

Q.4 Some more extensive data on disease intersecting genes and functional pathways should be included.

A network gallery is available under the "Browse Section". The visualization of the network of the intersecting genes with D3-Fore is available. These networks have been generated using GeneMania plugin from Cytoscape. Further, the analysis was also done to elaborate the Gene Ontology for the intersecting DEGs, the data is available in Appendix-VI. Further, we aim to build more towards the on this in our future studies. ADMET studies have also been included.

Competing Interests: No competing interests declared

Reviewer Report 04 January 2021

<https://doi.org/10.5256/f1000research.28377.r75389>

© 2021 Begum R et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mitesh Dwivedi

C.G. Bhakta Institute of Biotechnology, Faculty of Science, Uka Tarsadia University, Surat, Gujarat, India

Rasheedunnisa Begum

Department of Biochemistry, Faculty of Science, Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India

The study presented by Srivastava *et al.* (2020) is a unique approach to elucidate the link between Vitiligo and associated autoimmune disorders through a set of differentially co-expressed genes involved in their pathogenesis. For this, authors have designed a valuable tool called VIRdb 2.0: an integrative database that can be utilized by researchers and clinicians for drug development for vitiligo.

Authors have well explained the need and rationale for developing this new software tool. This database has been connected to KEGG, STRING, GeneCards, SwissProt, & NPASS. The different datasets can be easily downloaded by the user such as protein target information, differential expression of genes, docking results with natural compounds, and interaction network. In addition, VIRdb 2.0 also has a separate blog section where researchers can write interesting and updated informative blogs.

Overall, the software seems to be user friendly, though certain information and functionalities about submission of data by other researchers working in the fields of Vitiligo and its associated diseases is lacking in this version. The below are a few suggestions and concerns which authors should consider and implement in the future version of the VIRdb 2.0.

Conceptual concerns:

1. Though VIRdb 2.0 has included information on certain autoimmune disorders associated with Vitiligo (i.e. Psoriasis, Multiple Sclerosis and Rheumatoid Arthritis); it is lacking a few other important autoimmune diseases which are frequently associated with vitiligo such as autoimmune thyroid disease, adult-onset type 1 diabetes mellitus, pernicious anemia, systemic lupus erythematosus, and Addison disease.^{1,2}
2. Further, in the study, it is not clear which type of Vitiligo has been taken into account. It would be interesting and rather more significant if authors could integrate the different types of Vitiligo into consideration. Since the disease pathology varies between different types of Vitiligo as well as disease activity can further be considered in such DEG and gene interaction studies.
3. The demographic data of such patients can be linked along with the details of the type of disease, disease onset, duration of disease, VASI score, disease activity, etc. These data would be more meaningful with respect to the treatment aspect as well and can be very well correlated with the gene expression data in Vitiligo as well as associated autoimmune diseases.
4. Another important aspect to confirm in the present study is that: Did the data used by the authors for the differentially expressed genes in each disease were validated with respect to medication? Importantly, whether the expression data obtained from the patients differentiate who were on treatment or without treatment? Because treatment would surely affect the gene expression in these patients. Hence, it would be good if the authors could segregate and take the data accordingly.
5. Authors must avoid the term 'auto-inflammatory disease' for Vitiligo. Vitiligo is an autoimmune disease. The autoinflammatory theory mentioned here is not the correct term to use and it must be 'autoimmune theory'. [The autoinflammatory theory is perhaps the most widely accepted theory that discusses the occurrence of Vitiligo.]

Technical and utility concerns:

1. The software should have features to generate clustered heat maps for the selected DEGs in vitiligo, psoriasis, RA and MS.
2. The software should also provide an option to compare DEG in lesional skin vs non-lesional skin of vitiligo patients.
3. Similarly, the software should provide an option to compare DEG within different types of vitiligo, for example, generalized vitiligo vs localized vitiligo.
4. The software should provide features to generate boxplots for the expression values for genes comparing expression between vitiligo (lesional, non-lesionals) and the different disease conditions (vitiligo, psoriasis, RA, MS).
5. It would be good to add features in the software to search the levels of a particular gene from the database.
6. The software should add the data of DEGs within particular cells/tissue and features to

compare the DEG within different cell types/tissues.

7. The software should provide an option to carry out a meta-analysis of a particular gene in all the disease conditions (vitiligo, psoriasis, RA, MS), which would be beneficial to understand their role in the cross talk between the different disease conditions (vitiligo, psoriasis, RA, MS).
8. The software should have features to link the DEG to their respective signaling pathways, which will be crucial to pinpoint the role of the altered gene expression in these conditions.
9. The software should have an option to compare DEG of the available genes for drug treated group vs non-treated group.
10. The authors should provide video tutorials for the different features of the software, which will be helpful for first time users to easily navigate through the user interface.
11. Figures in the article could be provided with good resolution. The labeling and annotation in the figures are not visualized clearly (especially in Fig. 1, 2, 4 & 5C).

References

1. Alkhateeb A, Fain PR, Thody A, Bennett DC, et al.: Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. *Pigment Cell Res.* 2003; **16** (3): 208-14 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Laberge G, Mailloux CM, Gowan K, Holland P, et al.: Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. *Pigment Cell Res.* 2005; **18** (4): 300-5 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the rationale for developing the new software tool clearly explained?

Yes

Is the description of the software tool technically sound?

Yes

Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?

Partly

Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?

Partly

Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunogenetics, disease biology, vitiligo, autoimmunity

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Reviewer Report 21 September 2020

<https://doi.org/10.5256/f1000research.28377.r70478>

© 2020 Gupta D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dinesh Gupta

Translational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, Delhi, India

VIRdb2.0 is an integrative database for vitiligo research, integrating its links to Psoriasis, Multiple Sclerosis, Rheumatoid Arthritis, and Diabetes. The database release 2.0 is developed with additional features over the previous version.

Summarily, the database is a collection of differentially co-expressed genes involved in the crosstalks with Vitiligo and associated autoimmune disorders. This looks like a good resource for researchers interested in Vitiligo research. Few concerns and suggestions, which the authors should address:

1. The manuscript should illustrate a few specific examples to demonstrate the utility of the database, apart from showing the overall capabilities.
2. The database site should include a tutorial for users, demonstrating the database tools and searches.
3. A new page to be created to highlight "what's new in this release".
4. It will be nice if the authors could include gene regulatory networks too, involving the role of common TFs in the related diseases.
5. It will be nice if some data on the druggability of a few common hubs could be highlighted too.
6. Few logical search options should be considered to make the database search more useful.

Is the rationale for developing the new software tool clearly explained?

Yes

Is the description of the software tool technically sound?

Yes

Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?

Partly

Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?

Partly

Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Translational Bioinformatics, Systems biology, database, and algorithm development.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 27 Jan 2021

Abhishek Sengupta

Dear Sir,

We thank you for the generous and concise comments on our manuscript. We have incorporated the suggestions and changes have been added to the manuscript text also.

Q.1 The manuscript should illustrate a few specific examples to demonstrate the utility of the database, apart from showing the overall capabilities.

As per the suggestion, we have incorporated a case study at the Home page of the database, which demonstrates the use of the database to construct an interaction network for the intersecting genes between Rheumatoid Arthritis and Vitiligo and further use Cytoscape tool to import and analyse the network using mCODE app as a demonstration of the utility of the database.

Q.2 The database site should include a tutorial for users, demonstrating the database tools and searches.

A short tutorial has been incorporated at the Home page highlighting the sections and the process of retrieval from the sections. Complete code for accessing the database is already available at GitHub.

Q.3 A new page to be created to highlight "what's new in this release".

A new page has been created to highlight "what's new in this release" as advised.

Q.4 It will be nice if the authors could include gene regulatory networks too, involving the role of common TFs in the related diseases.

A network gallery is available under the "Browse Section". The visualization of the

network of the intersecting genes with D3-Fore is available. These networks have been generated using GeneMania plugin from Cytoscape. Further, the analysis was also done to elaborate the Gene Ontology for the intersecting DEGs, the data is available in Appendix-VI. Further, we aim to build more towards the on this in our future studies.

Q.5 It will be nice if some data on the druggability of a few common hubs could be highlighted too.

We have incorporated ADMET studies for the compounds that we have used for the purpose of screening and the excel files are also available in the "Downloads Section"

Q.6 Few logical search options should be considered to make the database search more useful.

Since, this is a static database, for now, we will incorporate the logical search options in our next version of the database/tool.

Competing Interests: No competing interests declared.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research